Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716770 | 1.00 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL1670578 | 1.00 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL31491210 | 0.92 | ALDH1A1 (0.47) | LMNACYP2D6MAPK1CA1CA2 | |
| SCHEMBL6447396 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL3071 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL719256 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL7758366 | 0.89 | LMNA (0.51) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL715653 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL7354344 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL717091 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2300197-A | — | — | None | — | — | JP | disclosed |
| EP-4019528-B1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | SHENZHEN YUNHE PHARMACEUTICAL TECH PARTNERSHIP LIMITED (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | SHENZHEN YUNHE PHARMACEUTICAL TECHNOLOGY PARTNERSHIP (LIMITED) (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-118638140-A | Oxo-substituted compounds | 住友制药株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-112135830-B | Oxo-substituted compounds | 住友制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-116925168-A | Bile acid derivatives, compositions and uses thereof | 深圳云合医药科技合伙企业(有限合伙) | 2023-10-24 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| EP-0388982-A1 | Pradimicin amide derivatives | Bristol-Myers Squibb Company (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0227306-B1 | PEPTIDE IMMUNOSTIMULANTS | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4767743-A | ANTIINFECTION AGENTS | PFIZER INC. (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0103077-B1 | SUBSTITUTED DIPEPTIDES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD FOR MAKING SUCH PHARMACEUTICAL COMPOSITIONS | SCHERING CORPORATION (US) | 1988-05-18 | — | — | EP | disclosed |
| WO-1988001613-A1 | CRYSTALLINE N-(S-3-METHYLHEPTANOYL)-D-GAMMA-GLUTAMYL-GLYCYL-D-ALANINE, AND PROCESSES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1988-03-10 | — | — | WO | disclosed |
| WO-1988001612-A1 | PROCESSES AND INTERMEDIATES FOR N-(S-3-ALKYL-HEPTANOYL)-D-GAMMA-GLUTAMYL-GLYCYL-D-ALANINE | PFIZER INC. (US) | 1988-03-10 | — | — | WO | disclosed |
| US-4590178-A | DIURETICS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1986-05-20 | — | — | US | disclosed |
| US-4536395-A | DIPEPTIDES | AJINOMOTO CO., INC. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4472381-A | Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them | AJINOMOTO COMPANY INCORPORATED (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0085488-A2 | Amino acid derivatives and antihypertensive drugs containing them | AJINOMOTO CO., INC. (JP) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | LMNA 1484/4885MAPT 4495/4885CYP2D6 241/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | LMNA 4744/4885MAPT 2134/4885CYP2D6 2744/4885 |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | NR1H4, GPBAR1, GLP1R | LMNA 4572/4885MAPT 4033/4885CYP2D6 638/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | LMNA 1484/4885MAPT 4495/4885CYP2D6 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.